CA2400488A1 - Procedes destines a la prevention et au traitement d'infetions au moyen d'anticorps anti-c3b(i) - Google Patents

Procedes destines a la prevention et au traitement d'infetions au moyen d'anticorps anti-c3b(i) Download PDF

Info

Publication number
CA2400488A1
CA2400488A1 CA002400488A CA2400488A CA2400488A1 CA 2400488 A1 CA2400488 A1 CA 2400488A1 CA 002400488 A CA002400488 A CA 002400488A CA 2400488 A CA2400488 A CA 2400488A CA 2400488 A1 CA2400488 A1 CA 2400488A1
Authority
CA
Canada
Prior art keywords
antibodies
composition
cells
cancer
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002400488A
Other languages
English (en)
Inventor
Ronald P. Taylor
Margaret A. Lindorfer
William M. Sutherland
Joanna B. Goldberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Virginia Patent Foundation
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2400488A1 publication Critical patent/CA2400488A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne le traitement et la prévention d'infections virales, et de chocs septiques par administration d'anticorps anti-C3b(i). Cette invention concerne également des procédés destinés au traitement et à la prévention d'infections virales, d'infections microbiennes ou de chocs sceptiques chez un animal qui consistent à administrer à cet animal des anticorps IgG, des anticorps IgM et/ou des composants du complément en combinaison avec des anticorps immunospécifiques aux C3b(i). L'invention concerne en outre des procédés destinés au traitement et à la prévention d'infections virales ou d'infections microbiennes chez un animal qui consistent à administrer à cet animal des anticorps qui se lient de façon immunospécifique à un ou plusieurs antigènes viraux ou microbiens, respectivement, en combinaison avec des anticorps immunospécifiques aux C3b(i). L'invention concerne enfin des procédés destinés au traitement et à la prévention de chocs sceptiques chez un animal qui consistent à administrer à cet animal des anticorps qui se lient de façon immunospécifique au lipopolysaccharide, une endotoxine ou un constituant de la paroi extérieure d'une bactérie gram négatif en combinaison avec des anticorps immunospécifiques aux C3b(i).
CA002400488A 2000-02-08 2001-02-08 Procedes destines a la prevention et au traitement d'infetions au moyen d'anticorps anti-c3b(i) Abandoned CA2400488A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18114300P 2000-02-08 2000-02-08
US60/181,143 2000-02-08
US72462100A 2000-11-28 2000-11-28
US09/724,621 2000-11-28
PCT/US2001/004020 WO2001058483A2 (fr) 2000-02-08 2001-02-08 Procedes destines a la prevention et au traitement d'infetions au moyen d'anticorps anti-c3b(i)

Publications (1)

Publication Number Publication Date
CA2400488A1 true CA2400488A1 (fr) 2001-08-16

Family

ID=26876927

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002400488A Abandoned CA2400488A1 (fr) 2000-02-08 2001-02-08 Procedes destines a la prevention et au traitement d'infetions au moyen d'anticorps anti-c3b(i)

Country Status (5)

Country Link
EP (1) EP1257583A2 (fr)
JP (1) JP2003522159A (fr)
AU (1) AU2001234925A1 (fr)
CA (1) CA2400488A1 (fr)
WO (1) WO2001058483A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572856B1 (en) * 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
AU2002306728B2 (en) * 2001-03-15 2007-12-13 Elusys Therapeutics, Inc. Polyclonal populations of bispecific molecules and methods of production and uses thereof
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
ES2387275T3 (es) * 2003-05-15 2012-09-19 Genentech, Inc. Métodos y composiciones para la prevención y el tratamiento de la sepsis
NZ546554A (en) 2003-10-10 2009-04-30 Powderject Vaccines Inc Nucleic acid constructs
AU2011242413A1 (en) * 2010-04-23 2012-11-29 Probiotec Limited Cold treatment
CN110865182B (zh) * 2019-11-19 2023-06-27 东莞市东阳光诊断产品有限公司 一种阻断剂及其在免疫检测中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE452065B (sv) * 1986-04-11 1987-11-09 Ulf R Nilsson Antikroppspreparation vars antikroppar er specifika for determinanter i c3 b regionen hos denaturerat humant c3 samt dess anvendning och framstellning
IL141936A0 (en) * 1998-09-10 2002-03-10 Univ Virginia Antibodies to c3b(1) for delivery of diagnostic and therapeutic agents to cancer cells

Also Published As

Publication number Publication date
EP1257583A2 (fr) 2002-11-20
AU2001234925A1 (en) 2001-08-20
JP2003522159A (ja) 2003-07-22
WO2001058483A3 (fr) 2002-04-18
WO2001058483A2 (fr) 2001-08-16

Similar Documents

Publication Publication Date Title
US6572856B1 (en) Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
ES2550621T3 (es) Anticuerpos anti-CD19 y usos en oncología
JP6530044B2 (ja) 癌療法のためのａｂｃｂ５標的化
JP4303964B2 (ja) 組換え抗ｃｄ３０抗体およびその使用
US8066996B2 (en) Anti-CCR7 receptor antibodies for the treatment of cancer
US10087258B2 (en) Anti-CD324 monoclonal antibodies and uses thereof
US9884915B2 (en) Antibodies against CCR9 and methods of use thereof
JP2017500028A (ja) 新規の抗ｄｐｅｐ３抗体および使用方法
TW200823237A (en) Antibodies to NTB-A
AU765585B2 (en) Antibodies to C3b(I) for delivery of diagnostic and therapeutic agents to cancer cells
CA2400488A1 (fr) Procedes destines a la prevention et au traitement d'infetions au moyen d'anticorps anti-c3b(i)
ZA200101999B (en) Antibodies to C3B(1) for delivery of diagnostic and therapeutic agents to cancer cells.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20080208